Barclays Maintains Overweight on Tango Therapeutics, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Tango Therapeutics (NASDAQ:TNGX) but lowers the price target from $18 to $13.
May 24, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Tango Therapeutics but lowers the price target from $18 to $13.
The lowered price target from $18 to $13 suggests a less optimistic outlook for Tango Therapeutics, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100